Research graph
References from CRISPR therapy for dyslipidemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
10.1016/s0140-6736(10)61350-5 · 2010 · External reference
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 · External reference
The forgotten majority: unfinished business in cardiovascular risk reduction
10.1016/j.jacc.2005.07.006 · 2005 · External reference
EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study
10.1093/eurjpc/zwaa047 · 2021 · External reference
High-intensity statin use among patients with atherosclerosis in the U.S
10.1016/j.jacc.2022.02.048 · 2022 · External reference
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
10.5114/aoms.2015.49807 · 2015 · External reference
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study
10.1093/eurheartj/ehv641 · 2016 · External reference
Overcoming clinical inertia to improve the use of cardiovascular risk reducing therapy: a Fellow's Voice
10.1016/j.ajpc.2024.100671 · 2024 · External reference
Patterns of statin use in a real-world population of patients at high cardiovascular risk
2016 · External reference
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
10.1111/bcp.12339 · 2014 · External reference
Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe
10.1001/jamanetworkopen.2018.5554 · 2018 · External reference
Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease
10.1001/jama.2019.14120 · 2019 · External reference
Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement
10.1093/eurheartj/ehag382 · 2026 · External reference
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
10.1056/nejmoa2215024 · 2023 · External reference
Safety and efficacy of obicetrapib in patients at high cardiovascular risk
10.1056/nejmoa2415820 · 2025 · External reference
Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial
10.1001/jama.2025.20620 · 2025 · External reference
10.1016/j.jacadv.2026.102733
10.1016/j.jacadv.2026.102733 · 2026 · External reference
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
10.1016/j.jacc.2007.10.038 · 2008 · External reference
Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease
10.1161/atvbaha.116.308305 · 2016 · External reference
Apolipoprotein B particles and cardiovascular disease: a narrative review
10.1001/jamacardio.2019.3780 · 2019 · External reference
A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies
10.1016/j.jacc.2016.11.042 · 2017 · External reference
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
10.1056/nejmoa064278 · 2007 · External reference
Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease
10.1001/jama.2018.20045 · 2019 · External reference
Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis
10.1001/jamacardio.2018.1470 · 2018 · External reference
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
10.1016/s0140-6736(12)60312-2 · 2012 · External reference
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
10.1056/nejmoa1812792 · 2019 · External reference
Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial
10.1001/jama.2020.22258 · 2020 · External reference
Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial
10.1001/jamacardio.2024.0959 · 2024 · External reference
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
10.1056/nejmoa2404147 · 2024 · External reference
Lipoprotein(a) reduction in persons with cardiovascular disease
10.1056/nejmoa1905239 · 2020 · External reference
Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease
10.1056/nejmoa2211023 · 2022 · External reference
Lepodisiran – a long-duration small interfering RNA targeting lipoprotein(a)
10.1056/nejmoa2415818 · 2025 · External reference
Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.4504 · 2024 · External reference
Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.24017 · 2025 · External reference
Effect of serial infusions of CER-001, a prebeta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial
10.1001/jamacardio.2018.2121 · 2018 · External reference
Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT Trial: a randomized clinical trial
10.1001/jamacardio.2018.2112 · 2018 · External reference
Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial Infarction
10.1056/nejmoa2400969 · 2024 · External reference
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
10.1056/nejmoa1609581 · 2017 · External reference
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
10.1056/nejmoa1107579 · 2011 · External reference
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
10.1038/s41591-026-04441-3 · 2026 · External reference
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
10.1126/science.1225829 · 2012 · External reference
CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia
10.1056/nejmoa2031054 · 2021 · External reference
Base editing: advances and therapeutic opportunities
10.1038/s41573-020-0084-6 · 2020 · External reference
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
10.1038/s41586-024-07087-8 · 2024 · External reference
Establishing, maintaining and modifying DNA methylation patterns in plants and animals
10.1038/nrg2719 · 2010 · External reference
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels
10.1038/s41591-025-03508-x · 2025 · External reference
Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components
10.1021/acs.molpharmaceut.1c00916 · 2022 · External reference
Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease
10.1056/nejmoa1612790 · 2017 · External reference
Evinacumab for homozygous familial hypercholesterolemia
10.1056/nejmoa2004215 · 2020 · External reference
Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3
10.1056/nejmoa2511778 · 2025 · External reference
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
10.1038/ng1161 · 2003 · External reference
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
10.1038/ng1509 · 2005 · External reference
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
10.1056/nejmoa054013 · 2006 · External reference
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
10.1016/j.jacc.2014.03.019 · 2014 · External reference
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial,
10.1016/j.jacl.2015.08.006 · 2015 · External reference
Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the Gauss-3 randomized clinical trial
10.1001/jama.2016.3608 · 2016 · External reference
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
10.1056/nejmoa1105803 · 2012 · External reference
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
10.1001/jama.2014.4030 · 2014 · External reference
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
10.1056/nejmoa1316222 · 2014 · External reference
Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial
10.1001/jama.2016.16951 · 2016 · External reference
Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction
10.1016/j.jcmg.2022.03.002 · 2022 · External reference
Evolocumab in patients without a previous myocardial infarction or stroke
10.1056/nejmoa2514428 · 2026 · External reference
Evolocumab and clinical outcomes in patients with cardiovascular disease
10.1056/nejmoa1615664 · 2017 · External reference
Alirocumab and cardiovascular outcomes after acute coronary syndrome
10.1056/nejmoa1801174 · 2018 · External reference
In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia
10.1056/nejmoa2601283 · 2026 · External reference
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
10.1001/jama.2014.4030 · ExternalCitation · doi-reference
Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV Randomized Clinical Trial
10.1001/jama.2016.16951 · ExternalCitation · doi-reference
Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the Gauss-3 randomized clinical trial
10.1001/jama.2016.3608 · ExternalCitation · doi-reference
Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease
10.1001/jama.2018.20045 · ExternalCitation · doi-reference
Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease
10.1001/jama.2019.14120 · ExternalCitation · doi-reference
Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH Randomized Clinical Trial
10.1001/jama.2020.22258 · ExternalCitation · doi-reference
Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.24017 · ExternalCitation · doi-reference
Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a): a randomized clinical trial
10.1001/jama.2024.4504 · ExternalCitation · doi-reference
Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial
10.1001/jama.2025.20620 · ExternalCitation · doi-reference
Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis
10.1001/jamacardio.2018.1470 · ExternalCitation · doi-reference
Effect of infusion of high-density lipoprotein mimetic containing recombinant apolipoprotein A-I Milano on coronary disease in patients with an acute coronary syndrome in the MILANO-PILOT Trial: a randomized clinical trial
10.1001/jamacardio.2018.2112 · ExternalCitation · doi-reference
Effect of serial infusions of CER-001, a prebeta high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 atherosclerosis regression acute coronary syndrome trial: a randomized clinical trial
10.1001/jamacardio.2018.2121 · ExternalCitation · doi-reference
Apolipoprotein B particles and cardiovascular disease: a narrative review
10.1001/jamacardio.2019.3780 · ExternalCitation · doi-reference
Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 Randomized Clinical Trial
10.1001/jamacardio.2024.0959 · ExternalCitation · doi-reference
Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe
10.1001/jamanetworkopen.2018.5554 · ExternalCitation · doi-reference
Overcoming clinical inertia to improve the use of cardiovascular risk reducing therapy: a Fellow's Voice
10.1016/j.ajpc.2024.100671 · ExternalCitation · doi-reference
10.1016/j.jacadv.2026.102733
10.1016/j.jacadv.2026.102733 · ExternalCitation · doi-reference
The forgotten majority: unfinished business in cardiovascular risk reduction
10.1016/j.jacc.2005.07.006 · ExternalCitation · doi-reference
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
10.1016/j.jacc.2007.10.038 · ExternalCitation · doi-reference
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab
10.1016/j.jacc.2014.03.019 · ExternalCitation · doi-reference
A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies
10.1016/j.jacc.2016.11.042 · ExternalCitation · doi-reference
High-intensity statin use among patients with atherosclerosis in the U.S
10.1016/j.jacc.2022.02.048 · ExternalCitation · doi-reference
Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial,
10.1016/j.jacl.2015.08.006 · ExternalCitation · doi-reference
Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction
10.1016/j.jcmg.2022.03.002 · ExternalCitation · doi-reference
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
10.1016/s0140-6736(10)61350-5 · ExternalCitation · doi-reference
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
10.1016/s0140-6736(12)60312-2 · ExternalCitation · doi-reference
Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components
10.1021/acs.molpharmaceut.1c00916 · ExternalCitation · doi-reference
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
10.1038/ng1161 · ExternalCitation · doi-reference
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
10.1038/ng1509 · ExternalCitation · doi-reference
Establishing, maintaining and modifying DNA methylation patterns in plants and animals
10.1038/nrg2719 · ExternalCitation · doi-reference
Base editing: advances and therapeutic opportunities
10.1038/s41573-020-0084-6 · ExternalCitation · doi-reference
Durable and efficient gene silencing in vivo by hit-and-run epigenome editing
10.1038/s41586-024-07087-8 · ExternalCitation · doi-reference
A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels
10.1038/s41591-025-03508-x · ExternalCitation · doi-reference
AAV gene therapy for homozygous familial hypercholesterolemia: a phase 1 trial
10.1038/s41591-026-04441-3 · ExternalCitation · doi-reference
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
10.1056/nejmoa054013 · ExternalCitation · doi-reference
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
10.1056/nejmoa064278 · ExternalCitation · doi-reference
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol
10.1056/nejmoa1105803 · ExternalCitation · doi-reference
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
10.1056/nejmoa1107579 · ExternalCitation · doi-reference
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia
10.1056/nejmoa1316222 · ExternalCitation · doi-reference
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
10.1056/nejmoa1609581 · ExternalCitation · doi-reference
Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease
10.1056/nejmoa1612790 · ExternalCitation · doi-reference
Evolocumab and clinical outcomes in patients with cardiovascular disease
10.1056/nejmoa1615664 · ExternalCitation · doi-reference
Alirocumab and cardiovascular outcomes after acute coronary syndrome
10.1056/nejmoa1801174 · ExternalCitation · doi-reference
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia
10.1056/nejmoa1812792 · ExternalCitation · doi-reference
Lipoprotein(a) reduction in persons with cardiovascular disease
10.1056/nejmoa1905239 · ExternalCitation · doi-reference
Evinacumab for homozygous familial hypercholesterolemia
10.1056/nejmoa2004215 · ExternalCitation · doi-reference
CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia
10.1056/nejmoa2031054 · ExternalCitation · doi-reference
Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease
10.1056/nejmoa2211023 · ExternalCitation · doi-reference
Bempedoic acid and cardiovascular outcomes in statin-intolerant patients
10.1056/nejmoa2215024 · ExternalCitation · doi-reference
Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial Infarction
10.1056/nejmoa2400969 · ExternalCitation · doi-reference
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia
10.1056/nejmoa2404147 · ExternalCitation · doi-reference
Lepodisiran – a long-duration small interfering RNA targeting lipoprotein(a)
10.1056/nejmoa2415818 · ExternalCitation · doi-reference
Safety and efficacy of obicetrapib in patients at high cardiovascular risk
10.1056/nejmoa2415820 · ExternalCitation · doi-reference
Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3
10.1056/nejmoa2511778 · ExternalCitation · doi-reference
Evolocumab in patients without a previous myocardial infarction or stroke
10.1056/nejmoa2514428 · ExternalCitation · doi-reference
In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia
10.1056/nejmoa2601283 · ExternalCitation · doi-reference
Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement
10.1093/eurheartj/ehag382 · ExternalCitation · doi-reference
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study
10.1093/eurheartj/ehv641 · ExternalCitation · doi-reference
EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study
10.1093/eurjpc/zwaa047 · ExternalCitation · doi-reference
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
10.1111/bcp.12339 · ExternalCitation · doi-reference
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity
10.1126/science.1225829 · ExternalCitation · doi-reference
Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease
10.1161/atvbaha.116.308305 · ExternalCitation · doi-reference
Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
10.5114/aoms.2015.49807 · ExternalCitation · doi-reference
